RedShift BioAnalytics announces partnership with DKSH, expanding the MMS market in Asia Pacific
RedShift BioAnalytics, a leading supplier of life science instruments, to distribute its products in Korea, Taiwan, Singapore, and Thailand through distribution partnership with DKSH
Burlington, MA, March 30, 2022 – RedShift BioAnalytics (RedShiftBio®) has entered a partnership with DKSH Business Unit Technology, which will provide sales, marketing, and after-sales services in Korea, Taiwan, Singapore, and Thailand.
RedShiftBio’s flagship instrument, the AQS³pro, provides users with in-depth structural information in a single automated analysis through a powerful analytical technique called Microfluidic Modulation Spectroscopy (MMS). MMS overcomes many of the limitations of traditional spectroscopy-based technologies with ultrasensitive and highly reproducible structural measurements of proteins and other biomolecules. It can be used for a wide range of applications from formulation development of mAb-based biotherapeutics to robust measurements of ADCs, AAVs, and mRNA.
”The successful adoption of the AQS³pro throughout the biopharmaceutical industry highlights the critical value our technology provides with ultra-sensitive measurements of biomolecule structure,” said Julien Bradley, Chief Executive Officer of RedShiftBio. “Our partnership with DKSH will expand global access to our MMS technology, providing more users with a new level of insight to accelerate and de-risk drug development.”
Marco Farina, Senior Director-Business Development, Business Unit Technology, commented: “Expanding our life science portfolio and accelerating our growth for the business are DKSH’s key initiatives. Partnering with RedShiftBio complements our workflow of protein characterization. We are excited to introduce RedShiftBio’s leading solutions to our customers.”
About RedShift BioAnalytics
RedShiftBio® is a forward-thinking technology company providing a novel life sciences platform for reliable and accurate detection of pivotal changes in molecular structure that affect the critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS), that provides in-depth structural information in a single automated analysis. RedShiftBio is headquartered out of Burlington, Massachusetts. For more information, please visit www.redshiftbio.com.
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our business Units Healthcare, Consumer Goods, Performance Materials, and technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution, and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Technology offers complete solutions for specialized industrial applications. With around 1,600 specialists, the Business Unit generated net sales of CHF 430.3 million in 2021. www.dksh.com/tec
For further information, please contact:
Director, Marketing and Communications -RedShiftBio